Phase 1 with Expansion Cohorts in a Study of NEO-201 in Adults with Chemo-Resistant Solid tumors

This is a first-in-human phase 1 study to determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of NEO-201 in adults with advanced solid tumors that have high likelihood of expression NEO201 antigen and have progressed to standard of treatments.

Authors:

M. Pia Morelli, Nicole D. Houston, Stan Lipkowitz, Jung-min Lee, Alexandra Dos Santos Zimmer, Farah Z. Zia, Kathrine Trewhitt, Erin Nichols, Mira Pavelova, Stephen M. Hewitt, Massimo Fantini, Philip M. Arlen, Kwong Y. Tsang, Christina M. Annunziata; NCI, Bethesda, MD; Women’s Malignancies Branch, National Cancer Institute, Bethesda, MD; National Cancer Institute, Bethesda, MD; National Cancer Institute Women’s Malignancies Branch, Bethesda, MD; National Cancer Institute, National Institutes of Health, Bethesda, MD; Natl Cancer Inst, Bethesda, MD; WMB National Cancer Institute, Bethesda, MD; Frederick National Laboratory for Cancer Research, Frederick, MD; National Institutes of Health, Bethesda, MD; Laboratory of Pathology, CCR, NCI, NIH, Bethesda, MD; Precision Biologics, Bethesda, MD